February 28, 2023 — 06:31 pm EST

      Written by
                        RTTNews.com for                             
        




RTTNews ->


(RTTNews) - Nektar Therapeutics (NKTR) announced Loss for fourth quarter that decreased from last year and  beat the Street estimates.
The company's bottom line totaled -$59.69 million, or -$0.32 per share.  This compares with -$145.65 million, or -$0.79 per share, in last year's fourth quarter.
Analysts on average had expected the company to earn -$0.45 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter fell 12.0% to $22.02 million from $25.01 million last year.
Nektar Therapeutics earnings at a glance (GAAP) :
-Earnings (Q4): -$59.69 Mln. vs. -$145.65 Mln. last year.
-EPS (Q4): -$0.32 vs. -$0.79 last year.
-Analyst Estimates: -$0.45
-Revenue (Q4): $22.02 Mln vs. $25.01 Mln last year.
 
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

© 2023, Nasdaq, Inc. All Rights Reserved.










To add symbols:


These symbols will be available throughout the site during your session.
To add symbols:


These symbols will be available throughout the site during your session.